Pfizer, Novartis set to cash in on rofecoxib withdrawal

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.463, 2004-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rofecoxib

By Scott L.J.   Lamb H.M.  

Drugs, Vol. 58, Iss. 3, 1999-09 ,pp. : 499-505

Adis International

Access to resources Recommend Favorite

Rofecoxib

By Hillson J.L.   Furst D.E.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 5, 2000-07 ,pp. : 1053-1066

Informa Healthcare

Access to resources Recommend Favorite

Since Novartis' COX-2 inhibitor lumiracoxib [`Prexige'] has failed to demonstrate features differentiating it from the class leader celecoxib [`Celebrex; Pfizer/Pharmacia'], it could have limited market success

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 403, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

The safety of rofecoxib

By Burnier Michel  

Expert Opinion on Drug Safety, Vol. 4, Iss. 3, 2005-05 ,pp. : 491-499

Informa Healthcare

Access to resources Recommend Favorite

Pfizer pulls the plug on Mylotarg

By  

Reactions Weekly, Vol. 1, Iss. 1307, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite